unveiled MyCell™ Services,
which include novel iPS cell
line reprogramming from a
customer-donated human tissue
sample, genetic engineering,
and differentiation of iPS cells
into commercially available
iCell terminal tissue cells, such
as cardiomyocytes, neurons,
endothelial cells, or hepatocytes.
“
Our current iCell products
provide a cellular model of a
normal, healthy human donor.
However, researchers may
want to study specific ethnic or
disease patient populations, and
MyCell Services enable them to
obtain those iPS cells or tissue
cells through CDI’s stem cell and
manufacturing expertise,” says
omesin Dapi
onizes Our Approach to Health page 349
September 2012
